glp-1 select trial Efficacy and safety of a novel dual GIP and receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 Clinical efficacy results from clinical

"Oral methionine compared with intravenous n-acetyl cysteine for paracetamol overdose." Emerg

Since the introduction of medical nutrition therapy, it has been used to treat heart disease

Available from: Bao X, Qian K, Yao P

Meanwhile, Chinese companies are rapidly advancing through fast following, innovation and licensing, with key developments including Innovents mazdutide, Innogens supaglutide, Hengruis oral candidate HRS-7535, United Laboratories licensing of its first-in-class triple-G (GLP-1, gastric inhibitory polypeptide (GIP) and glucagon) a gonist to Novo Nordisk and Ascletis positive Phase 1 results for its oral + injection candidate, ASC30

doi:10.1016/j.nbd.2013.10.017